valproic acid has been researched along with Bone Cancer in 12 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have examined the effects of the repurposed drugs, bezafibrate, medroxyprogesterone acetate and valproic acid on human osteosarcoma cells, i." | 8.02 | Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells. ( Bunce, CM; Ellington, MA; Johnson, WE; Khanim, FL; MacKay, HL; Sheard, JJ; Snow, MD; Southam, AD, 2021) |
| " The aim of the present study was to investigate the effects of sodium valproate (VPA), a histone deacetylase inhibitor, in combination with hydralazine hydrochloride (Hy), a DNA methylation inhibitor, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells." | 7.91 | Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. ( Fujihara, Y; Futani, H; Kobayashi, K; Kumanishi, S; Nakasho, K; Nishiura, H; Yamanegi, K; Yoshiya, S, 2019) |
| "In this study, we performed combination treatment of caffeine and valproic acid on osteosarcoma cell lines in vitro and in spontaneous and experimental lung metastasis mouse models of osteosarcoma." | 7.85 | Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice. ( Hayashi, K; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Miwa, S; Murakami, T; Tsuchiya, H; Yamamoto, N, 2017) |
| "Both valproic acid and caffeine caused concentration-dependent cell death of the osteosarcoma cell lines in vitro." | 7.83 | Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models. ( Hayashi, K; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N, 2016) |
| "Valproic acid, a histone deacetylase inhibitor, increases the expression of cell surface MHC class I-related chain molecules (MICs) A and B (MICA and B) in osteosarcoma cells and decreases their secretion of soluble MICA and MICB, which are produced by the proteolytic cleavage of cell surface MICs." | 7.78 | Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. ( Fukunaga, S; Futani, H; Hata, M; Kobayashi, K; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K, 2012) |
| " We have examined the effects of the repurposed drugs, bezafibrate, medroxyprogesterone acetate and valproic acid on human osteosarcoma cells, i." | 4.02 | Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells. ( Bunce, CM; Ellington, MA; Johnson, WE; Khanim, FL; MacKay, HL; Sheard, JJ; Snow, MD; Southam, AD, 2021) |
| " The aim of the present study was to investigate the effects of sodium valproate (VPA), a histone deacetylase inhibitor, in combination with hydralazine hydrochloride (Hy), a DNA methylation inhibitor, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells." | 3.91 | Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. ( Fujihara, Y; Futani, H; Kobayashi, K; Kumanishi, S; Nakasho, K; Nishiura, H; Yamanegi, K; Yoshiya, S, 2019) |
| " Here, we investigated the effects of the HDAC inhibitor valproic acid (VPA) and the demethylating agent, 5'azacytidine (DAC) on the stem phenotype of MG63 and Saos2 osteosarcoma cell lines." | 3.88 | HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. ( Desiderio, V; La Noce, M; Lombardi, A; Mele, L; Paino, F; Papaccio, F; Papaccio, G; Regad, T; Tirino, V, 2018) |
| "In this study, we performed combination treatment of caffeine and valproic acid on osteosarcoma cell lines in vitro and in spontaneous and experimental lung metastasis mouse models of osteosarcoma." | 3.85 | Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice. ( Hayashi, K; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Miwa, S; Murakami, T; Tsuchiya, H; Yamamoto, N, 2017) |
| "Both valproic acid and caffeine caused concentration-dependent cell death of the osteosarcoma cell lines in vitro." | 3.83 | Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models. ( Hayashi, K; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N, 2016) |
| "Valproic acid, a histone deacetylase inhibitor, increases the expression of cell surface MHC class I-related chain molecules (MICs) A and B (MICA and B) in osteosarcoma cells and decreases their secretion of soluble MICA and MICB, which are produced by the proteolytic cleavage of cell surface MICs." | 3.78 | Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. ( Fukunaga, S; Futani, H; Hata, M; Kobayashi, K; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K, 2012) |
| "Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines." | 3.75 | Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. ( Futani, H; Hata, M; Kato-Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K, 2009) |
| "In a sample of archival human osteosarcoma tumor specimens, expression of Hes1 mRNA was inversely correlated with survival (n=16 samples, p=0." | 2.45 | How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. ( Hughes, DP, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sawai, T | 1 |
| Yamanegi, K | 5 |
| Nishiura, H | 2 |
| Futani, H | 5 |
| Tachibana, T | 1 |
| Sheard, JJ | 1 |
| Southam, AD | 1 |
| MacKay, HL | 1 |
| Ellington, MA | 1 |
| Snow, MD | 1 |
| Khanim, FL | 1 |
| Bunce, CM | 1 |
| Johnson, WE | 1 |
| Igarashi, K | 2 |
| Kawaguchi, K | 1 |
| Kiyuna, T | 1 |
| Murakami, T | 1 |
| Yamamoto, N | 2 |
| Hayashi, K | 2 |
| Kimura, H | 2 |
| Miwa, S | 2 |
| Tsuchiya, H | 2 |
| Hoffman, RM | 2 |
| La Noce, M | 1 |
| Paino, F | 1 |
| Mele, L | 1 |
| Papaccio, G | 1 |
| Regad, T | 1 |
| Lombardi, A | 1 |
| Papaccio, F | 1 |
| Desiderio, V | 1 |
| Tirino, V | 1 |
| Kumanishi, S | 1 |
| Fujihara, Y | 1 |
| Kobayashi, K | 3 |
| Nakasho, K | 4 |
| Yoshiya, S | 1 |
| Wang, CK | 1 |
| Yu, XD | 1 |
| Li, Q | 1 |
| Xie, G | 1 |
| Teng, Y | 1 |
| Takeuchi, A | 1 |
| Yamane, J | 3 |
| Hata, M | 3 |
| Ohyama, H | 3 |
| Yamada, N | 3 |
| Kato-Kogoe, N | 2 |
| Okamura, H | 3 |
| Terada, N | 3 |
| Hughes, DP | 1 |
| Nishioka, T | 1 |
| Fukunaga, S | 2 |
| Wittenburg, LA | 1 |
| Ptitsyn, AA | 1 |
| Thamm, DH | 1 |
1 review available for valproic acid and Bone Cancer
| Article | Year |
|---|---|
How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.
Topics: Basic Helix-Loop-Helix Transcription Factors; Bone Development; Bone Neoplasms; Histone Deacetylase | 2009 |
11 other studies available for valproic acid and Bone Cancer
| Article | Year |
|---|---|
Sodium Valproate Enhances Semaphorin 3A-mediated Anti-angiogenesis and Tumor Growth Inhibition in Human Osteosarcoma Cells.
Topics: Bone Neoplasms; Histone Deacetylase Inhibitors; Humans; Neovascularization, Pathologic; Neuropilin-1 | 2023 |
Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells.
Topics: Bezafibrate; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Repositioni | 2021 |
Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Cell Death; Cell | 2017 |
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
Topics: Animals; Azacitidine; Bone Neoplasms; Cell Line, Tumor; DNA Methylation; Heterografts; Histone Deace | 2018 |
Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Topics: Bone Neoplasms; Cell Line; Cell Line, Tumor; Drug Synergism; Endothelial Cells; Enzyme Inhibitors; E | 2019 |
Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line.
Topics: Anticonvulsants; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, | 2013 |
Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Caspase 3; Caspas | 2016 |
Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.
Topics: Antibodies; Bone Neoplasms; Cell Death; Cell Proliferation; Down-Regulation; Drug Evaluation, Precli | 2009 |
Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Topics: Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; Cell Membrane; Combined Modality Therapy; Gene | 2010 |
A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Dogs; Down-Regulation; Endothelin- | 2012 |
Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells.
Topics: Bone Neoplasms; Cell Line, Tumor; Dipeptides; Down-Regulation; Histocompatibility Antigens Class I; | 2012 |